Therapy Areas: Inflammatory Diseases
NeuroSense reports Phase 2 proof-of-concept study results for PrimeC in Alzheimer's Disease
26 June 2026 - Late-clinical stage biotechnology company NeuroSense Therapeutics Ltd (NASDAQ:NRSN) on Thursday reported positive biomarker findings from its Phase 2 randomised, double-blind, placebo-c...
Vascarta announces VAS-101 Phase I results in sickle cell disease patients
25 June 2026 - Clinical-stage biopharmaceutical company Vascarta Inc announced on Wednesday the successful completion of the sublingual arm of its Phase I clinical trial evaluating VAS-101 (Vasceptor;...
Cirius Therapeutics commences enrolment and dosing for Phase 2 study of CIR-0602K in type 1 diabetes
25 June 2026 - Cirius Therapeutics Inc, a developer of innovative therapies for people suffering from diseases caused by mitochondrial dysfunction and insulin resistance, announced on Wednesday that e...
Kither Biotech completes Phase 1 KIT2014 clinical study
22 June 2026 - Kither Biotech Pty Ltd and Kither Biotech srl, an Italy-based clinical-stage biopharmaceutical group of companies developing innovative therapies for respiratory diseases, announced on ...
Gesynta Pharma reports progress in Phase 2 trial of vipoglanstat
18 June 2026 - Swedish clinical-stage pharmaceutical company Gesynta Pharma AB announced on Wednesday that 50% of the target of 190 patients have been randomised in its Phase 2 clinical proof-of-conce...
Hillhurst Bio reports first subject dosed in Phase 2a trial of HBI-002 for Parkinson's disease
16 June 2026 - Hillhurst Biopharmaceuticals Inc, a clinical-stage biopharmaceutical company focused on developing novel oral liquid drug products based on known inhaled therapeutics, announced on Mond...